Yoshinori Ito

Dr. Yoshinori Ito

Department of Pediatrics and Child Health, Nihon University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Vaccine
Verified
Journal Article
Open access
YKYoshihiko Kawano
Yoshihiko Kawano
MSMichio Suzuki
Michio Suzuki
JKJun-Ichi Kawada
Jun-Ichi Kawada
HKHiroshi Kimura
Hiroshi Kimura
HKHideya Kamei
Hideya Kamei
YIYoshinori Ito
Yoshinori Ito
Liver transplantation recipients are at high risk for severe complications due to infections because of being treated with immunosuppressive drugs that affect the immune system. Vaccination for liver transplantation candidates is generally recommended before surgery, but the opportunities for vaccination prior to transplantation in pediatric candidates are often limited by severe disease conditions. The participants in this study comprised 39 pediatric recipients of living donor liver transplantation performed between 2005 and 2013. Criteria for administering live-attenuated (measles, rubella, mumps, and varicella) and inactivated (hepatitis B, pertussis, and Japanese encephalitis) vaccines were as follows: (1) >1 year after transplantation; (2) no use of systemic steroids to treat acute rejection within the last 6 months; (3) serum trough concentration of tacrolimus <5 ng/mL; (4) no severe immunosuppression according to blood examinations; and (5) provision of written informed consent. Median age at transplantation was 17 months, and median period from transplantation to the beginning of immunization was 18 months. Seroprotection rates for measles, rubella, mumps, varicella, hepatitis B, pertussis, and Japanese encephalitis after post-transplant immunization were 44% (11/25), 70% (19/27), 48% (12/25), 32% (6/19), 83% (19/23), 87% (13/15), and 88% (7/8), respectively. Seroprotection rates for measles, rubella, mumps, and varicella after second vaccination for recipients with primary vaccine failure after first vaccination were 100% (8/8), 50% (1/2), 71% (5/7), and 50% (5/10), respectively. While four recipients contracted mumps and eight contracted varicella before immunization, one recipient developed varicella after immunization. No serious systemic adverse events were observed in vaccinated recipients. Seroprotection rates for measles, mumps, and varicella appeared low in children after the first post-transplantation vaccination. Immunizations with four live-attenuated and three inactivated vaccines were safe and effective for pediatric liver transplantation recipients who were not severely immunosuppressed.

17 May 2013 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
YKYoshihiko Kawano
Yoshihiko Kawano
SISeiko Iwata
Seiko Iwata
JKJun-Ichi Kawada
Jun-Ichi Kawada
KGKensei Gotoh
Kensei Gotoh
MSMichio Suzuki
Michio Suzuki
YIYoshinori Ito
Yoshinori Ito
Background. Chronic active Epstein–Barr virus (CAEBV) infection has high mortality and morbidity, and biomarkers for disease severity and prognosis are required. MicroRNAs (miRNAs) are small noncoding RNAs, and EBV encodes multiple miRNAs. Because plasma contains sufficiently stable miRNAs, circulating EBV–associated miRNA profiles were investigated as novel biomarkers in CAEBV infection. Methods. Plasma miRNA expression was assessed for 12 miRNAs encoded within 2 EBV open reading frames (BART and BHRF). Expression levels were investigated in 19 patients with CAEBV infection, 14 patients with infectious mononucleosis, and 11 healthy controls. Relative expression levels of plasma miRNAs were determined by TaqMan probe-based quantitative assay. Results. Plasma miR-BART1-5p, 2-5p, 5, and 22 levels in patients with CAEBV infection were significantly greater than those in patients with infectious mononucleosis and in controls. Plasma miR-BART2-5p, 4, 7, 13, 15, and 22 levels were significantly elevated in patients with CAEBV infection with systemic symptoms, compared with levels in patients with no systemic symptoms. The levels of miR-BART2-5p, 13, and 15 showed clinical cutoff values associated with specific clinical conditions, in contrast to plasma EBV loads. Conclusions. Levels of specific plasma EBV miRNAs were elevated differentially in patients with CAEBV infection. Several EBV miRNAs, particularly miR-BART2-5p, 13, and 15, are potentially biomarkers of disease severity or prognosis.

28 February 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KHKazuhiro Horiba
Kazuhiro Horiba
JKJun-Ichi Kawada
Jun-Ichi Kawada
YOYusuke Okuno
Yusuke Okuno
NTNobuyuki Tetsuka
Nobuyuki Tetsuka
TSTakako Suzuki
Takako Suzuki
YIYoshinori Ito
Yoshinori Ito
Bloodstream infection (BSI) is a severe complication in immunocompromised patients. Next-generation sequencing (NGS) allows us to analyze comprehensively and quantitatively all microorganisms present in a clinical sample. Thirty-five pediatric patients (12 with BSI and 23 with suspected BSI/negative blood culture) were enrolled. Plasma/serum samples were used for sequencing and the results were compared with those from blood culture. Sequencing reads of bacteria isolated in blood culture were identified by NGS in all plasma/serum samples at disease onset. Bacteria isolated in blood culture were identical to the dominant bacteria by NGS in 8 of 12 patients. Bacterial reads per million reads of the sequence depth (BR) > 200 and relative importance values of the dominant bacteria (P1) > 0.5 were employed to determine causative pathogens. Causative pathogens were detected using these criteria in 7 of 12 patients with BSI. Additionally, causative bacteria were detected in the plasma/serum at 7 days before disease onset in two patients with catheter-related BSI. Causative pathogens, including virus, were identified in three patients with suspected BSI. Lastly, a total of 62 resistance genes were detected by NGS. In conclusion, NGS is a new method to identify causative microorganisms in BSI and may predict BSI in some patients.

30 October 2014 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JKJun-Ichi Kawada
Jun-Ichi Kawada
YIYoshinori Ito
Yoshinori Ito
SISeiko Iwata
Seiko Iwata
MSMichio Suzuki
Michio Suzuki
YKYoshihiko Kawano
Yoshihiko Kawano
HKHiroshi Kimura
Hiroshi Kimura
Purpose: Epstein–Barr virus (EBV) infects B cells, as well as T cells and natural killer (NK) cells, and is associated with T or NK cell lymphoid malignancies. In various tumor cells, mTOR performs an essential function together with Akt with regard to cell growth. We investigated the effects of mTOR inhibitors on EBV-associated T- and NK-cell lymphomas.

1 November 2011 in Cytokine
Verified
Journal Article
Closed access
YIYoshinori Ito
Yoshinori Ito
YTYuka Torii
Yuka Torii
RORieko Ohta
Rieko Ohta
MIMasaki Imai
Masaki Imai
SHShinya Hara
Shinya Hara
HKHiroshi Kimura
Hiroshi Kimura

7 April 2015 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
YKYasuko Kamiya
Yasuko Kamiya
JKJun-Ichi Kawada
Jun-Ichi Kawada
YKYoshihiko Kawano
Yoshihiko Kawano
YTYuka Torii
Yuka Torii
SKShinji Kawabe
Shinji Kawabe
YIYoshinori Ito
Yoshinori Ito